Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Ulrika Harmenberg, Petteri Hervonen, Timo K. Joensuu, Raymond S. McDermott, Claes Ginman, Marjaana Luukkaa, Paul Nyandoto, Akseli Hemminki, Sten Nilsson, John McCaffrey, Raija Asola, Taina Turpeenniemi Hujanen, Fredrik Laestadius, Tiina Tasmuth, Katinka Sandberg, Maccon M. Keane, Ilari Lehtinen, Tiina Luukkaala, Heikki Joensuu, The Prosty Study Group
Institutions: Tampere University Hospital, Karolinska Institutet, Docrates Cancer Center, Tallaght University Hospital, Karlstad Central Hospital, Päijät-Hämeen Keskussairaala, Helsinki University Hospital, Karolinska University Hospital, Mater Misericordiae University Hospital, Satakunta Central Hospital, Oulu University Hospital, Tampere University, University of Tampere
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2467694273